Coleman assumes responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience. He takes over for Teri Lawver, who in October announced her plans to retire as CCO of the continuous glucose monitor (CGM) maker. At the time, Dexcom said Lawver would serve as a special advisor to the company through early 2025.
“Dexcom’s commitment to drive innovation in glucose biosensing and its unique long-term growth opportunity make the chief commercial officer role an incredible opportunity,” said Mr. Coleman. “I am excited to lead this great team at a key point in the company’s history and execute on the company’s ambitious vision to empower greater health around the world.”
Coleman brings more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. He spent 15 years at Masimo, serving as an executive officer in roles of increasing responsibility. That included leading Masimo’s commercial teams as president.
Additionally, Coleman held significant posts at Pfizer’s Consumer Healthcare business. He led as VP and GM of Canada and the Caribbean region after years spent leading in Asia and Latin America.
“Jon has demonstrated the ability to lead organizations through the complexities of global healthcare with consistently strong performance across a variety of sectors and channels,” said Kevin Sayer, chair, president and CEO at Dexcom. “This broad experience across market segments and regions provides a great fit as we look to capitalize on Dexcom’s incredible growth opportunity.”
